e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
Kevin R. Flaherty, Martin Kolb, Carlo Vancheri, Wenbo Tang, Craig S. Conoscenti, Luca Richeldi
Source:
Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017
Journal Issue:
August
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kevin R. Flaherty, Martin Kolb, Carlo Vancheri, Wenbo Tang, Craig S. Conoscenti, Luca Richeldi. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 830-836
Year: 2010
Early decrease of forced vital capacity is a good prediction tool for prognosis in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
Forced vital capacity decreases rapidly in patients with idiopathic upper lobe-dominant pulmonary fibrosis
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Source: Eur Respir Rev 2011; 20: 195-200
Year: 2011
Exercise capacity in idiopathic pulmonary fibrosis and COPD
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Post-bronchodilator FVC determines pulmonary rehabilitation outcomes in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions?
Year: 2011
The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
Source: International Congress 2016 – IPF treatment I
Year: 2016
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Determinants of exercise limitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 107s
Year: 2005
Effect of anti-acid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept